119 related articles for article (PubMed ID: 19114713)
1. Basic residues are critical to the activity of peptide inhibitors of human T cell leukemia virus type 1 entry.
Lamb D; Mirsaliotis A; Kelly SM; Brighty DW
J Biol Chem; 2009 Mar; 284(10):6575-84. PubMed ID: 19114713
[TBL] [Abstract][Full Text] [Related]
2. Highly specific inhibition of leukaemia virus membrane fusion by interaction of peptide antagonists with a conserved region of the coiled coil of envelope.
Lamb D; Schüttelkopf AW; van Aalten DM; Brighty DW
Retrovirology; 2008 Aug; 5():70. PubMed ID: 18680566
[TBL] [Abstract][Full Text] [Related]
3. Nonhelical leash and alpha-helical structures determine the potency of a peptide antagonist of human T-cell leukemia virus entry.
Mirsaliotis A; Lamb D; Brighty DW
J Virol; 2008 May; 82(10):4965-73. PubMed ID: 18305034
[TBL] [Abstract][Full Text] [Related]
4. An antiviral peptide targets a coiled-coil domain of the human T-cell leukemia virus envelope glycoprotein.
Piñón JD; Kelly SM; Price NC; Flanagan JU; Brighty DW
J Virol; 2003 Mar; 77(5):3281-90. PubMed ID: 12584351
[TBL] [Abstract][Full Text] [Related]
5. An antibody that blocks human T-cell leukemia virus type 1 six-helix-bundle formation in vitro identified by a novel assay for inhibitors of envelope function.
Mirsaliotis A; Nurkiyanova K; Lamb D; Kuo CS; Brighty DW
J Gen Virol; 2007 Feb; 88(Pt 2):660-669. PubMed ID: 17251585
[TBL] [Abstract][Full Text] [Related]
6. Conformation-specific antibodies targeting the trimer-of-hairpins motif of the human T-cell leukemia virus type 1 transmembrane glycoprotein recognize the viral envelope but fail to neutralize viral entry.
Mirsaliotis A; Nurkiyanova K; Lamb D; Woof JM; Brighty DW
J Virol; 2007 Jun; 81(11):6019-31. PubMed ID: 17376912
[TBL] [Abstract][Full Text] [Related]
7. Charge-surrounded pockets and electrostatic interactions with small ions modulate the activity of retroviral fusion proteins.
Lamb D; Schüttelkopf AW; van Aalten DM; Brighty DW
PLoS Pathog; 2011 Feb; 7(2):e1001268. PubMed ID: 21304939
[TBL] [Abstract][Full Text] [Related]
8. Molecular determinants of antiviral potency of paramyxovirus entry inhibitors.
Porotto M; Carta P; Deng Y; Kellogg GE; Whitt M; Lu M; Mungall BA; Moscona A
J Virol; 2007 Oct; 81(19):10567-74. PubMed ID: 17652384
[TBL] [Abstract][Full Text] [Related]
9. Small-molecule inhibitors of dengue-virus entry.
Schmidt AG; Lee K; Yang PL; Harrison SC
PLoS Pathog; 2012; 8(4):e1002627. PubMed ID: 22496653
[TBL] [Abstract][Full Text] [Related]
10. De novo design of peptide immunogens that mimic the coiled coil region of human T-cell leukemia virus type-1 glycoprotein 21 transmembrane subunit for induction of native protein reactive neutralizing antibodies.
Sundaram R; Lynch MP; Rawale SV; Sun Y; Kazanji M; Kaumaya PT
J Biol Chem; 2004 Jun; 279(23):24141-51. PubMed ID: 15060075
[TBL] [Abstract][Full Text] [Related]
11. Functional importance of the coiled-coil of the Ebola virus glycoprotein.
Watanabe S; Takada A; Watanabe T; Ito H; Kida H; Kawaoka Y
J Virol; 2000 Nov; 74(21):10194-201. PubMed ID: 11024148
[TBL] [Abstract][Full Text] [Related]
12. Resistance to neutralization by antibodies targeting the coiled coil of fusion-active envelope is a common feature of retroviruses.
Mirsaliotis A; Nurkiyanova K; Lamb D; Kuo CW; Brighty DW
J Biol Chem; 2007 Dec; 282(50):36724-35. PubMed ID: 17940280
[TBL] [Abstract][Full Text] [Related]
13. The ectodomain of the human T-cell leukemia virus type 1 TM glycoprotein is involved in postfusion events.
Rosenberg AR; Delamarre L; Pique C; Pham D; Dokhélar MC
J Virol; 1997 Oct; 71(10):7180-6. PubMed ID: 9311790
[TBL] [Abstract][Full Text] [Related]
14. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cell-free human T-cell leukemia virus type 1 infection at a postbinding step by the synthetic peptide derived from an ectodomain of the gp21 transmembrane glycoprotein.
Jinno A; Haraguchi Y; Shiraki H; Hoshino H
J Virol; 1999 Nov; 73(11):9683-9. PubMed ID: 10516085
[TBL] [Abstract][Full Text] [Related]
16. A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Tang X; Jin H; Chen Y; Li L; Zhu Y; Chong H; He Y
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462566
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides.
Malashkevich VN; Chan DC; Chutkowski CT; Kim PS
Proc Natl Acad Sci U S A; 1998 Aug; 95(16):9134-9. PubMed ID: 9689046
[TBL] [Abstract][Full Text] [Related]
18. Functional implications of the human T-lymphotropic virus type 1 transmembrane glycoprotein helical hairpin structure.
Maerz AL; Center RJ; Kemp BE; Kobe B; Poumbourios P
J Virol; 2000 Jul; 74(14):6614-21. PubMed ID: 10864675
[TBL] [Abstract][Full Text] [Related]
19. The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.
Moseri A; Biron Z; Arshava B; Scherf T; Naider F; Anglister J
FEBS J; 2015 Dec; 282(24):4643-57. PubMed ID: 26432362
[TBL] [Abstract][Full Text] [Related]
20. Pseudotyping of HIV-1 with Human T-Lymphotropic Virus 1 (HTLV-1) Envelope Glycoprotein during HIV-1-HTLV-1 Coinfection Facilitates Direct HIV-1 Infection of Female Genital Epithelial Cells: Implications for Sexual Transmission of HIV-1.
Tang Y; George AM; Petrechko O; Nouvet FJ; Sweet SD; Tanaka Y; Imbiakha BS; Jiang G; Gao W; Anastos K; Hildreth JEK
mSphere; 2018 Apr; 3(2):. PubMed ID: 29624497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
